Search

Your search keyword '"Guillaume Charpentier"' showing total 6 results
Start Over Author "Guillaume Charpentier" Journal canadian journal of diabetes
6 results on '"Guillaume Charpentier"'

1. Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5

Author

Louis Chaykin, Guillaume Charpentier, Desiree Thielke, Timothy Garvey, Julie Derving Karsbøl, Lawrence A. Leiter, Luis Masmiquel, and Mark Warren

Subjects
030213 general clinical medicine, business.industry, Endocrinology, Diabetes and Metabolism, Semaglutide, 030209 endocrinology & metabolism, General Medicine, Body weight, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal Medicine, Medicine, business, Baseline (configuration management), Demography
Published
2017
Full Text
View/download PDF

2. Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3)

Author

Miriam Annett, Andrew J. Ahmann, Anders G. Holst, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Ildiko Lingvay, Elena Henkel, and Vanita R. Aroda

Subjects
medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, Semaglutide, Once weekly, 030209 endocrinology & metabolism, General Medicine, Type 2 diabetes, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, 030212 general & internal medicine, business, Exenatide, medicine.drug
Published
2016
Full Text
View/download PDF

3. Effect of Type 2 Diabetes Disease Stage on Liraglutide Response in Clinical Practice: Data from the EVIDENCE® Study

Author

Luc Martinez, Alfred Penfornis, Pierre Gourdy, Jean-François Gautier, Guillaume Charpentier, Eveline Eschwège, and S. Madani

Subjects
medicine.medical_specialty, business.industry, Liraglutide, Endocrinology, Diabetes and Metabolism, Insulin, medicine.medical_treatment, General Medicine, Disease, Type 2 diabetes, medicine.disease, Clinical Practice, Endocrinology, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, In patient, Stage (cooking), business, medicine.drug
Abstract

s / Can J Diabetes 37 (2013) S13eS84 S41 OADs (25%) and insulin OADs (30%) vs. 1 or 2 OADs (19% to 21%). Withdrawals were mostly due to gastrointestinal disorders experienced early in the study. In summary, in routine clinical practice, response to liraglutide was greater in patients with shorter duration of diabetes and fewer background treatments.

Published
2013
Full Text
View/download PDF

4. Effectiveness of Liraglutide in Type 2 Diabetes Patients Switched from a DPP-4 Inhibitor: 1-Year Data from EVIDENCE®

Author

Jean-François Gautier, Luc Martinez, Alfred Penfornis, Eveline Eschwège, Guillaume Charpentier, Pierre Gourdy, and S. Madani

Subjects
Oncology, medicine.medical_specialty, business.industry, Liraglutide, Endocrinology, Diabetes and Metabolism, General Medicine, Type 2 diabetes, medicine.disease, Endocrinology, Internal medicine, Internal Medicine, Medicine, business, Dipeptidyl peptidase-4, medicine.drug
Published
2013
Full Text
View/download PDF

5. Effectiveness of Switching from a DPP-4 Inhibitor to the Human GLP-1 Analogue Liraglutide in Patients with Type 2 Diabetes

Author

S. Madani, Pierre Gourdy, Luc Martinez, Alfred Penfornis, Guillaume Charpentier, Jean-Francois Gauthier, Eveline Eschwège, and Lucette Farah

Subjects
Liraglutide, business.industry, Endocrinology, Diabetes and Metabolism, General Medicine, Type 2 diabetes, Pharmacology, medicine.disease, Endocrinology, Internal Medicine, medicine, In patient, GLP-1 Analogue, business, Dipeptidyl peptidase-4, medicine.drug
Published
2014
Full Text
View/download PDF

6. Effectiveness and Tolerability of Liraglutide Among Type 2 Diabetes Patients in Routine Clinical Practice: 1-Year Data from EVIDENCE®

Author

S. Madani, Jean-François Gautier, Eveline Eschwège, Guillaume Charpentier, Alfred Penfornis, Luc Martinez, and Pierre Gourdy

Subjects
medicine.medical_specialty, business.industry, Liraglutide, Endocrinology, Diabetes and Metabolism, General Medicine, Type 2 diabetes, medicine.disease, law.invention, Endocrinology, Tolerability, Randomized controlled trial, law, Sitagliptin, Internal medicine, Internal Medicine, medicine, Routine clinical practice, Observational study, business, medicine.drug, Glycemic
Abstract

observational, post-marketing outpatient study requested by the French National Health Authority to evaluate the effectiveness and safety of liraglutide. Objective: to determine percentage patients still taking liraglutide and at A1C target (

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results